Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.

Niveditha PutananickalElena C GrossAnna-Lena OrsiniSimone SchmidtPatricia HafnerVanya GochevaSara NagyBettina C HenziDaniela RubinoDeborah R VogtSven CichonPeter SandorDirk Fischer

Published in: Cephalalgia : an international journal of headache (2021)

The selected dose of supplemented exogenous DL-beta-hydroxybutyrate did not demonstrate efficacy in episodic migraineurs.ClinicalTrials.gov Identifier: NCT03132233.

Keyphrases

placebo controlled
double blind
phase iii
phase ii
study protocol
clinical trial
open label
phase ii study
randomized controlled trial
combination therapy
smoking cessation
replacement therapy